Neuranix announces a new completed capital injection and a reinforced shareholder structure
Summary
Its strategy is on one hand to serve in the future Paediatricians, Audiologists, ENTs surgery specialists and is eying also the hearing aid retail market. On the other hand, with Vet-Wave, Neuranix launched its first device for veterinary use: opening up new frontiers in veterinary screening and diagnostics by objectively measuring the middle ear functionality in dogs and cats.In addition to the existing shareholders - Founder and CEO Filip Moens, Biosline Holding and Lorenzo Caporaletti - new important investors bringing a wealth of experience in audiology diagnostic devices are; Kolind A/S, a personal holding owned by Lars Kolind, previously CEO of the Demant group, Mahalo Consulting, owned by S\xf8ren Holst, currently Director of Kolind A/S, President & CEO of Br\xfcel & Kj\xe6r - also previously President of Otometrics A/S, President of Oticon Inc. - and Peter Zoth, previously CEO of Path Medical and Founder of Fischer-Zoth.In addition to the industrial investors CDP Venture Capital (CDP) executed upon the conversion terms of a previous convertible loan and is now also fully present in the Neuranix shareholders structure. "These new investments will further help us with our veterinary business development activities, strengthen us in launching our first PLAI audiology screening & diagnostic device for the human ENT market in 2023 and allow us to continue our R&D efforts for our new product pipeline based on our solid patented technology. I am also extremely glad to be able to count on the expertise from S\xf8ren Holst, Peter Zoth and Fabio Gomiero, industry experts who will help Neuranix in the go-to-market initiatives and its next important future steps" said Filip E.A. Danish law firm DANDERS & MORE provided assistance to Kolind and Mahalo, one of the main investors, with a team led by partner Claus Abildstr\xf8m.